ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

22.16 -0.41 (-1.84%)

Streaming Delayed Price Updated: 10:12 AM EDT, Apr 10, 2026 Add to My Watchlist

Price and Volume

Volume	67,436
Open	22.52
Bid (Size)	22.13 (100)
Ask (Size)	22.18 (700)
Prev. Close	22.57
Today's Range	22.11 - 22.59
52wk Range	13.40 - 28.35
Shares Outstanding	162,625,379
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal

April 07, 2026

In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...

Via MarketMinute

Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit

April 07, 2026

The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most...

Via Finterra

Performance

YTD	-15.7%	-15.7%
1 Month	-1.7%	-1.7%
3 Month	-17.7%	-17.7%
6 Month	+7.4%	+7.4%
1 Year	+48.1%	+48.1%

More News

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

April 07, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Surpasses $1 Billion Revenue Milestone in 2025, Beats Q4 EPS Estimates ↗

February 25, 2026

Via Chartmill

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Emerges as a Value Stock with Strong Fundamentals ↗

February 06, 2026

Via Chartmill

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗

January 16, 2026

Via Chartmill

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar

April 06, 2026

Via MarketMinute

Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

March 12, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

March 03, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

Via The Motley Fool

Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

March 02, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

Via The Motley Fool

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

Via The Motley Fool

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗

February 27, 2026

Via Stocktwits

ACADIA (ACAD) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview

February 25, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

February 23, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Via The Motley Fool

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

Via The Motley Fool

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

February 04, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACAD Stock Slumps 8% After Hours On Hurdle To EU Approval For Genetic Disorder Drug ↗

February 02, 2026

Via Stocktwits

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

February 02, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

January 13, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

Via MarketMinute

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup for Breakout ↗

December 25, 2025

Via Chartmill

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?

Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.

What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?

ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?

The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market

What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?

The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 22.16

When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?

The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 04/10/26 10:12 AM ET

What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?

The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 3.60B

How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?

ACADIA Pharmaceuticals Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.